31.19
Schlusskurs vom Vortag:
$31.12
Offen:
$30.5
24-Stunden-Volumen:
457.89K
Relative Volume:
0.19
Marktkapitalisierung:
$5.88B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-12.94
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
-6.86%
1M Leistung:
+7.43%
6M Leistung:
+29.84%
1J Leistung:
-12.37%
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Vergleichen Sie BBIO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
BBIO
Bridgebio Pharma Inc
|
31.25 | 5.88B | 217.77M | -438.86M | -456.33M | -2.41 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
449.54 | 117.23B | 10.63B | -479.80M | -1.35B | -1.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
661.70 | 72.75B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
647.63 | 38.65B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
264.22 | 34.69B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
113.28 | 27.45B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
2024-10-03 | Eingeleitet | Oppenheimer | Perform |
2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
2024-03-21 | Fortgesetzt | Raymond James | Outperform |
2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
2023-11-07 | Eingeleitet | Citigroup | Buy |
2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
2023-02-06 | Eingeleitet | Cowen | Outperform |
2021-12-27 | Bestätigt | Mizuho | Buy |
2021-12-27 | Bestätigt | SVB Leerink | Outperform |
2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
2021-05-21 | Eingeleitet | UBS | Buy |
2021-03-22 | Bestätigt | Goldman | Buy |
2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
2021-02-09 | Fortgesetzt | Goldman | Buy |
2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
2020-05-19 | Eingeleitet | BTIG Research | Buy |
2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
2020-02-19 | Eingeleitet | Mizuho | Buy |
2019-07-26 | Eingeleitet | Raymond James | Outperform |
2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
2019-07-22 | Eingeleitet | Goldman | Buy |
2019-07-22 | Eingeleitet | JP Morgan | Overweight |
2019-07-22 | Eingeleitet | Jefferies | Buy |
2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio shares rise on Scotiabank price target boost By Investing.com - Investing.com South Africa
BridgeBio gets EU nod for ATTR cardiomyopathy drug - pharmaphorum
EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment - Yahoo Finance
BridgeBio wins EU approval for Beyonttra for ATTR-CM - The Pharma Letter
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK - BioPharma Dive
BridgeBio Pharma Says Beyonttra Gets EU Marketing Approval for Transthyretin Amyloidosis - Marketscreener.com
BridgeBio announces EC marketing authorization for BETONTTRA - TipRanks
BEYONTTRA™ (acoramidis), the First Near Complete TTR - GlobeNewswire
BBIO Secures Major EU Win: Revolutionary Heart Drug Shows 42% Mortality Reduction - StockTitan
BridgeBio's Heart Disease Drug Meets Late-stage End Points - BW Healthcare World
Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts - Insider Monkey
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 5.5% Following Insider Selling - MarketBeat
BridgeBio: Post Attruby Approval, Shares Don't Look Such Good ValueRating Downgrade - Seeking Alpha
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Update - MarketBeat
How To Trade (BBIO) - Stock Traders Daily
BBIO (BridgeBio Pharma) Operating Cash Flow per Share : $-2.50 (TTM As of Sep. 2024) - GuruFocus.com
Why BridgeBio Pharma Inc. (BBIO) Crashed on Monday - Insider Monkey
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Major Shareholder Sells $106,989,998.40 in Stock - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells $2,467,720.00 in Stock - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 326,932 Shares - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
Andreas Halvorsen Reduces Stake in BridgeBio Pharma Inc - GuruFocus.com
BridgeBio Pharma Insider Sold Shares Worth $2,467,761, According to a Recent SEC Filing - Marketscreener.com
Brokerages Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) PT at $49.00 - MarketBeat
Is BridgeBio Pharma, Inc. (BBIO) the Unstoppable Stock to Buy in 2025? - Insider Monkey
BBIO (BridgeBio Pharma) Cash Flow for Dividends : $0.0 Mil (TTM As of Sep. 2024) - GuruFocus.com
BBIO (BridgeBio Pharma) EBITDA : $-350.3 Mil (TTM As of Sep. 2024) - GuruFocus.com
Why BridgeBio Pharma (BBIO) Is Skyrocketing Now - MSN
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
14,302 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Acquired by Atomi Financial Group Inc. - MarketBeat
(BBIO) Trading Report - Stock Traders Daily
Equities Analysts Set Expectations for BBIO FY2025 Earnings - MarketBeat
Research Analysts Issue Forecasts for BBIO FY2025 Earnings - Defense World
Leerink Partnrs Has Negative Estimate for BBIO Q4 Earnings - Defense World
Cantor Fitzgerald Predicts BBIO FY2025 Earnings - MarketBeat
Leerink Partnrs Analysts Reduce Earnings Estimates for BBIO - MarketBeat
BridgeBio’s Neil Kumar on an underdog drug launch and wooing deal-hungry investors - BioPharma Dive
Why Is Andreas Halvorsen Bullish On BridgeBio Pharma, Inc. (BBIO) Now? - Insider Monkey
First Week of March 21st Options Trading For BridgeBio Pharma (BBIO) - Nasdaq
Top 4 Health Care Stocks You May Want To Dump In Q1 - Benzinga
Moss Adams Wealth Advisors LLC Acquires New Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Up 12.7% in December - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 6.6%Time to Buy? - MarketBeat
Hypoparathyroidism Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bridgebio Pharma Inc-Aktie (BBIO) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
VIKING GLOBAL INVESTORS LP | 10% Owner |
Jan 31 '25 |
Sale |
34.90 |
3,065,616 |
106,989,998 |
22,055,375 |
STEPHENSON BRIAN C | Secretary, Treasurer & CFO |
Jan 28 '25 |
Option Exercise |
17.00 |
68,000 |
1,156,000 |
161,758 |
STEPHENSON BRIAN C | Secretary, Treasurer & CFO |
Jan 28 '25 |
Sale |
36.29 |
68,000 |
2,467,761 |
93,758 |
Kumar Neil | Chief Executive Officer |
Jan 28 '25 |
Sale |
36.29 |
326,932 |
11,863,381 |
5,371,515 |
Kumar Neil | Chief Executive Officer |
Jan 29 '25 |
Sale |
36.35 |
273,068 |
9,925,269 |
5,098,447 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):